Everything below concerns heptapeptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
More recent advances in synthetic platelet technology have focused on biomimetic approaches to replicate the essential functions of native platelets known as adhesion, aggregation, and clot formation. Platelet-mimetic nanoparticles are designed to imitate platelet behavior without the systemic risks associated with transfusion. These constructs can self-assemble into structures that bind to tumor endothelial cells and transform into nanofibers, initiating artificial coagulation at targeted sites. This ability to localize coagulation without systemic effects is being further researched for applications in treating both bleeding disorders and cancer, where controlled clotting is necessary to achieve positive patient outcomes. Emerging solutions for blood transfusions also aim to address current limitations of donor platelet products. Recent research has focused on creating synthetic platelet analogs that enable engineered constructs to selectively bind to thrombus sites, potentially enhancing the precision of clotting therapies for conditions such as thrombosis. Furthermore, integrating these platelet-mimetic features into drug delivery vehicles offers the potential for targeted therapies in cardiovascular disease, anti-inflammation treatments, and immunotherapies. Addressing safety, enhancing production methods, and managing regulatory approvals are challenges that need to be resolved before synthetic platelets can enter human clinical trial development and be routinely used in practice.
The conquest of Armanum (location unknown but proposed as Tall Bazi) with its ruler Rid-Adad and Ebla (55 kilometers southwest of modern Aleppo) by Naram-Sin (Ebla was also defeated by his grandfather Sargon) is known from one of his year names "The year the king went on a campaign in Amarnum" and from an Old Babylonian copy of a statue inscription (IM 85461) found at Ur. There are also three objects, a marble lamp, a stone plaque, and a copper bowl, inscribed "Naram-Sin, the mighty, king of the four quarters, conqueror of Armanum and Ebla.". In 2010 a new stele fragment (IM 221139) describing the campaign was found at Tulul al-Baqarat (thought to be the ancient city of Kesh.
West Yorkshire is a metropolitan and ceremonial county in the Yorkshire and the Humber region of England. It borders North Yorkshire to the north and east, South Yorkshire and Derbyshire to the south, Greater Manchester to the south-west, and Lancashire to the west. The city of Leeds is the largest settlement. The county has an area of 2,029 km2 (783 sq mi) and had an estimated population of 2,435,236 in 2024. The centre of the county is urbanised. Leeds is in the north-east, the city of Wakefield in the south-east, Huddersfield in the south-west, and the city of Bradford in the north-west. The outer areas of the county are rural. For local government purposes the county comprises five metropolitan boroughs: Bradford, Calderdale, Kirklees, Leeds, and Wakefield, which collaborate through West Yorkshire Combined Authority. The county was created in 1974, prior to which the area was within the West Riding of Yorkshire. The western part of West Yorkshire is in the South Pennines, and contains a small part of the Peak District National Park. It is characterised by steep valleys and is the source of the River Calder, which flows past Wakefield before meeting the Aire, which flows through Leeds, near Castleford. The landscape becomes flatter in the east, and the eastern boundary of the county is on the edge of the Vale of York. Remnants of strong coal, wool and iron ore industries remain in the county, having attracted people over the centuries, and this can be seen in the buildings and architecture.
Sources: en.wikipedia.org
== History == Biuret was first prepared and studied by Gustav Heinrich Wiedemann (1826–1899) for his doctoral dissertation, which was submitted in 1847. His findings were reported in several articles.
=== Lacrosse bro (Lax Bro) === Lax bro subculture is defined as a laid-back ("chill") lifestyle associated with lacrosse. The bounds of the subculture are loose, but its character traits include "understated confidence that critics call arrogance", long hair known as "lettuce," colorful board shorts, flat-brim baseball hats, and colorful half-calf socks. The bands O.A.R., Dispatch, and Dave Matthews Band are associated with lax bros. Typical lax bro attitude and style are common in middle schools and universities according to a 2012 report in The Boston Globe. Enthusiasts praise the subculture's sense of identity and popularization of a sport indigenous to the United States, while detractors take issue with the "preppie/frat boy image that glorifies elitism and wealth, and values flash over hard work".
Organs that are rich in loose connective tissue (such as the eyelids) are usually sites that undergo oedema, indicating kidney failure or nephrotic syndrome. Therefore, periorbital swelling is one characteristic finding in severe kidney disease.
Sources: en.wikipedia.org
=== Allied professions === The term medical technology may also refer to the duties performed by clinical laboratory professionals or medical technologists in various settings within the public and private sectors. The work of these professionals encompasses clinical applications of chemistry, genetics, hematology, immunohematology (blood banking), immunology, microbiology, serology, urinalysis, and miscellaneous body fluid analysis. Depending on location, educational level, and certifying body, these professionals may be referred to as biomedical scientists, medical laboratory scientists (MLS), medical technologists (MT), medical laboratory technologists and medical laboratory technicians.
Prions are proteins of particular amino acid sequences in particular conformations. They propagate themselves in host cells by making conformational changes in other molecules of protein with the same amino acid sequence, but with a different conformation that is functionally important or detrimental to the organism. Once the protein has been transconformed to the prion folding, it changes function. In turn, it can convey information into new cells and reconfigure more functional molecules of that sequence into the alternate prion form. In some types of prion in fungi, this change is continuous and direct; the information flow is Protein → Protein. Some scientists such as Alain E. Bussard and Eugene Koonin have argued that prion-mediated inheritance violates the central dogma of molecular biology. However, Rosalind Ridley in Molecular Pathology of the Prions (2001) has written that "The prion hypothesis is not heretical to the central dogma of molecular biology—that the information necessary to manufacture proteins is encoded in the nucleotide sequence of nucleic acid—because it does not claim that proteins replicate. Rather, it claims that there is a source of information within protein molecules that contributes to their biological function, and that this information can be passed on to other molecules."
A study conducted by Lawrence Witmer and Ryan Ridgely of Ohio University found that Tyrannosaurus shared the heightened sensory abilities of other coelurosaurs, highlighting relatively rapid and coordinated eye and head movements; an enhanced ability to sense low frequency sounds, which would allow tyrannosaurs to track prey movements from long distances; and an enhanced sense of smell. A study published by Kent Stevens concluded that Tyrannosaurus had keen vision. By applying modified perimetry to facial reconstructions of several dinosaurs including Tyrannosaurus, the study found that Tyrannosaurus had a binocular range of 55 degrees, surpassing that of modern hawks. Stevens estimated that Tyrannosaurus had 13 times the visual acuity of a human and surpassed the visual acuity of an eagle, which is 3.6 times that of a person. Stevens estimated a limiting far point (that is, the distance at which an object can be seen as separate from the horizon) as far as 6 km (3.7 mi) away, which is greater than the 1.6 km (1 mi) that a human can see. Thomas Holtz Jr. would note that high depth perception of Tyrannosaurus may have been due to the prey it had to hunt, noting that it had to hunt ceratopsians such as Triceratops, ankylosaurs such as Ankylosaurus, and hadrosaurs. He would suggest that this made precision more crucial for Tyrannosaurus enabling it to, "get in, get that blow in and take it down." In contrast, Acrocanthosaurus had limited depth perception because they hunted large sauropods, which were relatively rare during the time of Tyrannosaurus.
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.